<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02816957</url>
  </required_header>
  <id_info>
    <org_study_id>30794l03l16</org_study_id>
    <nct_id>NCT02816957</nct_id>
  </id_info>
  <brief_title>Benefits of Nigella Sativa in Children With Beta Thalassemia Major</brief_title>
  <acronym>Nigella</acronym>
  <official_title>Study of The Therapeutic Benefits of Nigella Sativa in Children With Beta Thalassemia Major</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the therapeutic effects health benefits, and immunological effect of Nigella sativa
      in children with beta thalassemia major.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study will be carried on children patients with Î²- thalassemia major attending The Hematology
      Unit of Pediatric Department at Tanta University Hospital. patients are divided into 2
      groups: patients in the control group, patients in the treatment group that will receive
      nigella sativa powder for 3 consecutive months. Then Evaluate the therapeutic effects health
      benefits, and immunological effect of Nigella sativa in children with beta thalassemia major.

      Evaluate the extent of clinical improvement, reductions in serum iron and ferritin,
      antioxidant status, treatment of the causes of hemolysis and other therapeutic benefits of
      Nigella sativa in those patient.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>malondialdehyde</measure>
    <time_frame>3 months</time_frame>
    <description>nmol serum level of malondialdehyde (nmol per liter)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cluster of differentation4 and 8(CD4 and CD8)</measure>
    <time_frame>3 months</time_frame>
    <description>CD4 and CD8 cell per cmm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>total antioxidant</measure>
    <time_frame>3 months</time_frame>
    <description>total antioxidant(mmol per liter)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum iron</measure>
    <time_frame>3 months</time_frame>
    <description>microgram per dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total iron binding capacity</measure>
    <time_frame>3 months</time_frame>
    <description>microgram per dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum ferritin</measure>
    <time_frame>3 months</time_frame>
    <description>ng per ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete blood count</measure>
    <time_frame>3 months</time_frame>
    <description>complete blood count</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Nigella Sativa With Beta Thalassemia Major</condition>
  <arm_group>
    <arm_group_label>patients receiving Nigella</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 patients in the treatment group that will receive nigella sativa powder (2 gm/day) for 3 consecutive months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients not received nigella as controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>40 patients in the control group will not receive nigella sativa and continued on the usual chelators</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nigella sativ</intervention_name>
    <description>nigella sativa powder (2 gm/day) for 3 consecutive months.</description>
    <arm_group_label>patients receiving Nigella</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Thalassemia with iron overload

        Exclusion Criteria:

          -  Thalassemia complicated with diabetes mellitus or hepatitis

          -  Patients who discontinue treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Ramadan ELshanshory, prof</last_name>
    <role>Study Director</role>
    <affiliation>professor of pediatrics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nahed Mohamed Habas, MD</last_name>
    <phone>01010560350</phone>
    <email>nahedhablas79@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nahed moh Hablas, MD</last_name>
    <phone>00201010560350</phone>
    <email>nahedhabls79@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine- Tanta University</name>
      <address>
        <city>Tanta</city>
        <state>Gharbia</state>
        <zip>0000</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed R El-Shanshory, MD</last_name>
      <phone>+201005680834</phone>
      <email>elshanshory@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Nahed M Hablas, MD</last_name>
      <phone>+201010560350</phone>
      <email>nahedhablas79@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mohamed M El-Shanshory, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nahed AR Hablas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Salah M El Sayed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2016</study_first_submitted>
  <study_first_submitted_qc>June 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

